Trials / Completed
CompletedNCT02608710
RDEA3170 PK/PD Study
A Phase 1, Randomized, Open-Label Study in Healthy Adult Male Subjects to Assess the Pharmacokinetics and Pharmacodynamics of RDEA3170
- Status
- Completed
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 40 (estimated)
- Sponsor
- Ardea Biosciences, Inc. · Industry
- Sex
- Male
- Age
- 18 Years – 65 Years
- Healthy volunteers
- Accepted
Summary
The purpose of this study is to examine the pharmacokinetic and pharmacodynamic effect of RDEA3170 when given as single or multiple doses
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | RDEA3170 4.5 mg | |
| DRUG | RDEA3170 6 mg | |
| DRUG | RDEA3170 12 mg |
Timeline
- Start date
- 2015-11-01
- Primary completion
- 2015-12-01
- Completion
- 2016-04-01
- First posted
- 2015-11-20
- Last updated
- 2016-09-02
Locations
1 site across 1 country: United States
Source: ClinicalTrials.gov record NCT02608710. Inclusion in this directory is not an endorsement.